𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment

✍ Scribed by G. E. G. Verhoef; P. Zachée; A. Ferrant; H. Demuynck; D. Selleslag; L. Van Hove; F. Deckers; M. A. Boogaerts

Publisher
Springer
Year
1992
Tongue
English
Weight
705 KB
Volume
64
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recombinant human erythropoietin for the
Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors
✍ León, Pedro; Jiménez, Miguel; Barona, Pascual; Sierrasesúmaga, Luis 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Background. Cancer is often associated with chronic anemia which frequently requires blood transfusions. This study was performed to assess the efficacy and safety of r-HuEPO therapy in children with cancer. Patients and methods. Twenty-five patients under 18 years of age with solid malignant

Utility of blasts with a clear halo arou
Utility of blasts with a clear halo around the nucleolus as a predictive indicator for disease progression in patients with myelodysplastic syndromes and aplastic anemia
✍ Iwao Emura; Takaaki Chou; Yosuke Imai; Toshio Kakihara; Keiko Asami; Makoto Nait 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 2 views

This study was designed to evaluate the utility of blasts with a clear halo around their nucleoli (BCHN) as a predictive indicator of disease progression in myelodysplastic syndromes (MDSs) and aplastic anemia (AA). Bone marrow aspirates from 75 patients with MDSs and 18 with AA were fixed in 95% et

Azacitidine for the treatment of lower r
Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program
✍ Pellegrino Musto; Luca Maurillo; Alessandra Spagnoli; Antonella Gozzini; Flavia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

## Abstract ## BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high‐risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have